baricitinib vs filgotinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Rheumatoid Arthritis

Shared mechanism: JAK · full Rheumatoid Arthritis pipeline

baricitinib · Olumiant

Marketed by Eli Lilly and partners

Approved in Rheumatoid Arthritissmall molecule
Reliable signal

NCT01710358 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo-controlled trial using a validated composite measure of rheumatoid arthritis response, and significantly more patients responded on baricitinib than on placebo.

Next expected readout: March 2027 · NCT04870203 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) (Week 12): ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001) (met)

Result source: NCT02265705

filgotinib · Jyseleca

Marketed by Gilead Sciences and partners

Phase 3 in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02873936 · Phase 3 · completed

This was a randomized, double-blind, placebo-controlled trial in 449 patients; the primary endpoint, ACR20 response at week 12 (a validated rheumatoid-arthritis disease-activity measure), was significantly higher with both filgotinib doses than placebo (66.0% and 57.5% vs 31.1%, both p<0.001).

Next expected readout: April 2029 · NCT06687551 (registry estimate)

Reported efficacy

Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20% Improvement (ACR20) Response at Week 12: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001) (met)

Result source: NCT02889796

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointbaricitinibfilgotinib
ACR2061.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
76.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181
ACR5044.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
64.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181
ACR7024.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
44.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181
DAS28-CRP remission—Trial running · NCT0487020354.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
HAQ-DI, change-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
-0.8 vs -0.6−0.2 vs placebo200 mg · wk 24 · n 475NCT02889796
36 other results
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181
Modified Sharp score, change0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
0.1 vs 0.4−0.2 vs placebo200 mg · wk 24 · n 467NCT02889796
9 other results
  • 0.2 vs 0.9 200 mg · wk 52 · n 468 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728

ACR20

baricitinib
61.7% vs 39.5%+22.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • 55.4% vs 27.3% 4 mg · wk 12 · n 177 · Phase 3 · primary NCT01721044
  • 65.9% vs 39.5% 2 mg · wk 12 · n 229 · Phase 3 · primary NCT01721057
  • 69.6% vs 40.2% wk 12 · n 487 · Phase 3 · primary NCT01710358
  • 58.6% vs 28.3% wk 12 · n 145 · Phase 3 · primary NCT02265705
  • 76.7% vs 61.9% wk 24 · n 159 · Phase 3 · primary NCT01711359
  • 78.1% vs 61.9% wk 24 · n 215 · Phase 3 · primary NCT01711359
  • 46.3% vs 27.3% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 44.8% vs 27.3% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 48.9% vs 27.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 73% vs 55.7% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 72.6% vs 55.7% wk 52 · n 215 · Phase 3 · secondary NCT01711359
filgotinib
76.6% vs 49.9%+26.7 vs placebo200 mg · wk 12 · n 475NCT02889796
51 other results
  • 69.8% vs 49.9% 100 mg · wk 12 · n 480 · Phase 3 · primary NCT02889796
  • 66% vs 31.1% 200 mg · wk 12 · n 147 · Phase 3 · primary NCT02873936
  • 57.5% vs 31.1% 100 mg · wk 12 · n 153 · Phase 3 · primary NCT02873936
  • 78.1% vs 71.4% 200 mg · wk 24 · n 210 · Phase 3 · primary NCT02886728
  • 81% vs 71.4% 200 mg · wk 24 · n 416 · Phase 3 · primary NCT02886728
  • 80.2% vs 71.4% 100 mg · wk 24 · n 207 · Phase 3 · primary NCT02886728
  • 82.9% vs 85.9% 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • 82.9% vs 86.9% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 78.1% vs 59.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 51.6% vs 31.8% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 37.3% vs 14.9% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 79.6% vs 85.9% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 79.2% vs 86.9% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 77.7% vs 59.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 31.8% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 27.5% vs 14.9% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 69.4% vs 34.5% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 51.7% vs 25.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 54.9% vs 34.5% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 44.4% vs 25.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 74.8% vs 61.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 76.2% vs 68.3% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 71.4% vs 59.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 52.4% vs 33.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 16.6% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 75% vs 61.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 75.5% vs 68.3% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 76.7% vs 59.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 62.3% vs 33.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 42.1% vs 16.6% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 73.4% vs 61.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 73.4% vs 68.3% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 72% vs 59.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 33.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 16.6% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 72.5% vs 29.2% 200 mg QD · wk 12 · n 69 · Phase 2 · primary NCT01894516
  • 68.6% vs 44.2% 200 mg QD · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 65.7% vs 29.2% 100 mg QD · wk 12 · n 70 · Phase 2 · primary NCT01894516
  • 63.5% vs 44.2% 100 mg QD · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 78.6% vs 44.2% 100 mg BID · wk 12 · n 84 · Phase 2 · primary NCT01888874
  • 66.7% vs 29.2% 50 mg QD · wk 12 · n 72 · Phase 2 · primary NCT01894516
  • 56.1% vs 44.2% 50 mg QD · wk 12 · n 82 · Phase 2 · primary NCT01888874
  • 60% vs 44.2% 50 mg BID · wk 12 · n 85 · Phase 2 · primary NCT01888874
  • 57% vs 44.2% 25 mg BID · wk 12 · n 86 · Phase 2 · primary NCT01888874
  • 73.3% vs 41.9% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 61.2% vs 41.9% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 79.8% vs 41.9% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 54.9% vs 41.9% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 60% vs 41.9% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 55.8% vs 41.9% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 81% vs 40.9% wk 12 · n 21 · Phase 2 · secondary NCT02885181

ACR50

baricitinib
44.1% vs 21.5%+22.6 vs placebo4 mg · wk 24 · n 227NCT01721057
13 other results
  • 29.4% vs 13.1% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 33.5% vs 12.7% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 28.2% vs 8% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 41.5% vs 21.5% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 23% vs 13.1% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 33.6% vs 12.7% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 20.1% vs 8% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 57.2% vs 37.6% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 61.9% vs 37.6% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 59.7% vs 43.3% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 63.3% vs 43.3% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 54.7% vs 32.9% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 60% vs 32.9% wk 12 · n 215 · Phase 3 · secondary NCT01711359
filgotinib
64.2% vs 66%−1.8 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 63.2% vs 63.4% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 57.9% vs 33.3% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 47.2% vs 19.8% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 22.3% vs 5.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.1% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 60.6% vs 66% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 57.7% vs 63.4% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 52.7% vs 33.3% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 36.5% vs 19.8% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 12.9% vs 5.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 5.8% vs 1.1% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 45.6% vs 18.9% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 42.9% vs 14.9% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 7.4% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 35.3% vs 18.9% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 32% vs 14.9% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 21.6% vs 7.4% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 61.4% vs 48.3% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 58.6% vs 48.6% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 58.1% vs 45.7% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 45.7% vs 28.4% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 25.7% vs 9.4% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 16.2% vs 2.9% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 62.3% vs 48.3% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 60.6% vs 48.6% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 61.5% vs 45.7% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 53.1% vs 28.4% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 29.3% vs 9.4% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 2.9% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 59.4% vs 48.3% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 55.6% vs 48.6% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 57% vs 45.7% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 44.4% vs 28.4% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 20.8% vs 9.4% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 9.2% vs 2.9% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 50% vs 16.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 43.5% vs 11.1% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 43% vs 15.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 31.9% vs 5.6% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 33.7% vs 12.8% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 23.2% vs 4.2% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 17.4% vs 7% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 21.7% vs 4.2% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 10.5% vs 5.8% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 7.2% vs 1.4% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.1% vs 16.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 16.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 37.1% vs 11.1% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 37.6% vs 15.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 54.8% vs 15.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 25.7% vs 5.6% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 35.3% vs 12.8% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 45.2% vs 12.8% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 4.2% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 32.9% vs 7% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 34.5% vs 7% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 7.1% vs 4.2% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 20% vs 5.8% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 21.4% vs 5.8% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 10% vs 1.4% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 4.7% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 35.4% vs 16.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 35.3% vs 16.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 34.7% vs 11.1% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 32.9% vs 15.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 15.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 16.7% vs 5.6% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 26.8% vs 12.8% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 34.1% vs 12.8% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 15.3% vs 4.2% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 13.4% vs 7% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 7% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 5.6% vs 4.2% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 5.8% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 11.8% vs 5.8% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 1.4% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 7.1% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 34.9% vs 16.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 27.9% vs 15.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 25.6% vs 12.8% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 15.1% vs 7% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 7% vs 5.8% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 3.5% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 47.6% vs 22.7% wk 12 · n 21 · Phase 2 · secondary NCT02885181

ACR70

baricitinib
24.2% vs 7.9%+16.3 vs placebo4 mg · wk 24 · n 227NCT01721057
17 other results
  • 16.9% vs 3.4% 4 mg · wk 24 · n 177 · Phase 3 · secondary NCT01721044
  • 18.1% vs 3.1% 4 mg · wk 12 · n 227 · Phase 3 · secondary NCT01721057
  • 11.3% vs 2.3% 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • 25.3% vs 7.9% 2 mg · wk 24 · n 229 · Phase 3 · secondary NCT01721057
  • 13.2% vs 3.4% 2 mg · wk 24 · n 174 · Phase 3 · secondary NCT01721044
  • 17.9% vs 3.1% 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • 12.6% vs 2.3% 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • 42.1% vs 25.2% wk 52 · n 159 · Phase 3 · secondary NCT01711359
  • 46% vs 25.2% wk 52 · n 215 · Phase 3 · secondary NCT01711359
  • 42.1% vs 21.4% wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • 39.5% vs 21.4% wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • 30.8% vs 15.7% wk 12 · n 159 · Phase 3 · secondary NCT01711359
  • 33.5% vs 15.7% wk 12 · n 215 · Phase 3 · secondary NCT01711359
  • 29% vs 0% 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 29% vs 0% 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 21% vs 0% 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • 13% vs 0% 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
filgotinib
44.4% vs 37.7%+6.7 vs placebo200 mg · wk 52 · n 475NCT02889796
87 other results
  • 40.2% vs 34.6% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 36.2% vs 14.9% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 26.1% vs 6.7% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 9.1% vs 1.5% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 2.7% vs 0.4% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 39% vs 37.7% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 35.4% vs 34.6% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 29.6% vs 14.9% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 18.5% vs 6.7% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 3.3% vs 1.5% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.3% vs 0.4% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 32% vs 8.1% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 21.8% vs 6.8% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 6.1% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 20.3% vs 8.1% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 14.4% vs 6.8% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 8.5% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 45.2% vs 29.8% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 39.5% vs 32.2% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 40% vs 26% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29% vs 13.2% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 11.4% vs 3.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 4.3% vs 0.7% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 47.8% vs 29.8% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 45.9% vs 32.2% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 43.8% vs 26% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 32.9% vs 13.2% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 13% vs 3.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 3.1% vs 0.7% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 40.1% vs 29.8% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 37.2% vs 32.2% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 40.1% vs 26% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 27.1% vs 13.2% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 6.3% vs 3.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 1.9% vs 0.7% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • 29.1% vs 9.3% 200 mg QD · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 13% vs 2.8% 200 mg QD · wk 12 · n 69 · Phase 2 · secondary NCT01894516
  • 24.4% vs 8.1% 200 mg QD · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 17.4% vs 2.8% 200 mg QD · wk 8 · n 69 · Phase 2 · secondary NCT01894516
  • 18.6% vs 7% 200 mg QD · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 11.6% vs 1.4% 200 mg QD · wk 4 · n 69 · Phase 2 · secondary NCT01894516
  • 4.7% vs 3.5% 200 mg QD · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 4.3% vs 2.8% 200 mg QD · wk 2 · n 69 · Phase 2 · secondary NCT01894516
  • 5.8% vs 1.2% 200 mg QD · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 200 mg QD · wk 1 · n 69 · Phase 2 · secondary NCT01894516
  • 1.2% vs 1.2% 200 mg QD · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 32.9% vs 9.3% 100 mg QD · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 39.3% vs 9.3% 100 mg BID · wk 24 · n 84 · Phase 2 · secondary NCT01888874
  • 18.6% vs 2.8% 100 mg QD · wk 12 · n 70 · Phase 2 · secondary NCT01894516
  • 21.2% vs 8.1% 100 mg QD · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 31% vs 8.1% 100 mg BID · wk 12 · n 84 · Phase 2 · secondary NCT01888874
  • 11.4% vs 2.8% 100 mg QD · wk 8 · n 70 · Phase 2 · secondary NCT01894516
  • 23.5% vs 7% 100 mg QD · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 27.4% vs 7% 100 mg BID · wk 8 · n 84 · Phase 2 · secondary NCT01888874
  • 5.7% vs 1.4% 100 mg QD · wk 4 · n 70 · Phase 2 · secondary NCT01894516
  • 14.1% vs 3.5% 100 mg QD · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 10.7% vs 3.5% 100 mg BID · wk 4 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 100 mg QD · wk 2 · n 70 · Phase 2 · secondary NCT01894516
  • 7.1% vs 1.2% 100 mg QD · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 3.6% vs 1.2% 100 mg BID · wk 2 · n 84 · Phase 2 · secondary NCT01888874
  • 1.4% vs 0% 100 mg QD · wk 1 · n 70 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 100 mg QD · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 4.8% vs 1.2% 100 mg BID · wk 1 · n 84 · Phase 2 · secondary NCT01888874
  • 22% vs 9.3% 50 mg QD · wk 24 · n 82 · Phase 2 · secondary NCT01888874
  • 23.5% vs 9.3% 50 mg BID · wk 24 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 2.8% 50 mg QD · wk 12 · n 72 · Phase 2 · secondary NCT01894516
  • 15.9% vs 8.1% 50 mg QD · wk 12 · n 82 · Phase 2 · secondary NCT01888874
  • 18.8% vs 8.1% 50 mg BID · wk 12 · n 85 · Phase 2 · secondary NCT01888874
  • 6.9% vs 2.8% 50 mg QD · wk 8 · n 72 · Phase 2 · secondary NCT01894516
  • 11% vs 7% 50 mg QD · wk 8 · n 82 · Phase 2 · secondary NCT01888874
  • 14.1% vs 7% 50 mg BID · wk 8 · n 85 · Phase 2 · secondary NCT01888874
  • 8.3% vs 1.4% 50 mg QD · wk 4 · n 72 · Phase 2 · secondary NCT01894516
  • 7.3% vs 3.5% 50 mg QD · wk 4 · n 82 · Phase 2 · secondary NCT01888874
  • 9.4% vs 3.5% 50 mg BID · wk 4 · n 85 · Phase 2 · secondary NCT01888874
  • 1.4% vs 2.8% 50 mg QD · wk 2 · n 72 · Phase 2 · secondary NCT01894516
  • 2.4% vs 1.2% 50 mg QD · wk 2 · n 82 · Phase 2 · secondary NCT01888874
  • 5.9% vs 1.2% 50 mg BID · wk 2 · n 85 · Phase 2 · secondary NCT01888874
  • 0% vs 0% 50 mg QD · wk 1 · n 72 · Phase 2 · secondary NCT01894516
  • 0% vs 1.2% 50 mg QD · wk 1 · n 82 · Phase 2 · secondary NCT01888874
  • 2.4% vs 1.2% 50 mg BID · wk 1 · n 85 · Phase 2 · secondary NCT01888874
  • 20.9% vs 9.3% 25 mg BID · wk 24 · n 86 · Phase 2 · secondary NCT01888874
  • 14% vs 8.1% 25 mg BID · wk 12 · n 86 · Phase 2 · secondary NCT01888874
  • 9.3% vs 7% 25 mg BID · wk 8 · n 86 · Phase 2 · secondary NCT01888874
  • 5.8% vs 3.5% 25 mg BID · wk 4 · n 86 · Phase 2 · secondary NCT01888874
  • 2.3% vs 1.2% 25 mg BID · wk 2 · n 86 · Phase 2 · secondary NCT01888874
  • 1.2% vs 1.2% 25 mg BID · wk 1 · n 86 · Phase 2 · secondary NCT01888874
  • 38.1% vs 13.6% wk 12 · n 21 · Phase 2 · secondary NCT02885181

DAS28-CRP remission

baricitinib
—Trial running · NCT04870203
filgotinib
54.5% vs 50.8%+3.7 vs placebo200 mg · wk 52 · n 475NCT02889796
35 other results
  • 50.3% vs 46.1% 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • 48.4% vs 16.2% 200 mg · wk 24 · n 475 · Phase 3 · secondary NCT02889796
  • 34.1% vs 9.3% 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • 13.7% vs 2.9% 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • 5.1% vs 0.6% 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • 44.8% vs 50.8% 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • 42.9% vs 46.1% 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • 35.2% vs 16.2% 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • 23.8% vs 9.3% 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • 8.8% vs 2.9% 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • 1.7% vs 0.6% 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • 30.6% vs 12.2% 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • 22.4% vs 8.1% 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • 10.2% vs 2.7% 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • 26.1% vs 12.2% 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • 25.5% vs 8.1% 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • 11.8% vs 2.7% 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • 46.2% vs 31.5% 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 43.3% vs 34.4% 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • 42.4% vs 29.1% 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 29.5% vs 17.1% 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • 19.5% vs 4.8% 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • 10% vs 1% 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • 53.4% vs 31.5% 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 52.6% vs 34.4% 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • 54.1% vs 29.1% 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 39.7% vs 17.1% 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • 16.6% vs 4.8% 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • 7.2% vs 1% 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • 43% vs 31.5% 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • 42% vs 34.4% 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • 42.5% vs 29.1% 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 31.9% vs 17.1% 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • 15% vs 4.8% 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • 4.3% vs 1% 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728

HAQ-DI, change

baricitinib
-0.5 vs -0.3−0.2 vs placebo4 mg · wk 12 · n 227NCT01721057
11 other results
  • -0.4 vs -0.2 4 mg · wk 12 · n 177 · Phase 3 · secondary NCT01721044
  • -0.5 vs -0.3 2 mg · wk 12 · n 229 · Phase 3 · secondary NCT01721057
  • -0.4 vs -0.2 2 mg · wk 12 · n 174 · Phase 3 · secondary NCT01721044
  • -0.7 vs -0.3 wk 12 · n 487 · Phase 3 · secondary NCT01710358
  • -0.6 vs -0.3 wk 12 · n 144 · Phase 3 · secondary NCT02265705
  • -1.0 vs -0.7 wk 24 · n 159 · Phase 3 · secondary NCT01711359
  • -0.9 vs -0.7 wk 24 · n 215 · Phase 3 · secondary NCT01711359
  • -0.5 vs -0.1 4 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 2 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.4 vs -0.1 8 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
  • -0.3 vs -0.1 1 mg · wk 12 · n 24 · Phase 2 · secondary NCT01469013
filgotinib
-0.8 vs -0.6−0.2 vs placebo200 mg · wk 24 · n 475NCT02889796
36 other results
  • -0.7 vs -0.4 200 mg · wk 12 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 36 · n 475 · Phase 3 · secondary NCT02889796
  • -0.4 vs -0.3 200 mg · wk 4 · n 475 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.1 200 mg · wk 2 · n 475 · Phase 3 · secondary NCT02889796
  • -0.9 vs -0.7 200 mg · wk 52 · n 475 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.6 100 mg · wk 24 · n 480 · Phase 3 · secondary NCT02889796
  • -0.6 vs -0.4 100 mg · wk 12 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 36 · n 480 · Phase 3 · secondary NCT02889796
  • -0.3 vs -0.3 100 mg · wk 4 · n 480 · Phase 3 · secondary NCT02889796
  • -0.2 vs -0.1 100 mg · wk 2 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.7 100 mg · wk 52 · n 480 · Phase 3 · secondary NCT02889796
  • -0.8 vs -0.4 200 mg · wk 24 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.2 200 mg · wk 12 · n 147 · Phase 3 · secondary NCT02873936
  • -0.4 vs -0.2 200 mg · wk 4 · n 147 · Phase 3 · secondary NCT02873936
  • -0.6 vs -0.4 100 mg · wk 24 · n 153 · Phase 3 · secondary NCT02873936
  • -0.5 vs -0.2 100 mg · wk 12 · n 153 · Phase 3 · secondary NCT02873936
  • -0.3 vs -0.2 100 mg · wk 4 · n 153 · Phase 3 · secondary NCT02873936
  • -0.9 vs -0.8 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 36 · n 210 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 200 mg · wk 4 · n 210 · Phase 3 · secondary NCT02886728
  • -0.3 vs -0.2 200 mg · wk 2 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 200 mg · wk 12 · n 416 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 200 mg · wk 36 · n 416 · Phase 3 · secondary NCT02886728
  • -0.6 vs -0.3 200 mg · wk 4 · n 416 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 200 mg · wk 2 · n 416 · Phase 3 · secondary NCT02886728
  • -1 vs -0.9 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.8 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • -0.8 vs -0.6 100 mg · wk 12 · n 207 · Phase 3 · secondary NCT02886728
  • -0.9 vs -0.9 100 mg · wk 36 · n 207 · Phase 3 · secondary NCT02886728
  • -0.5 vs -0.3 100 mg · wk 4 · n 207 · Phase 3 · secondary NCT02886728
  • -0.4 vs -0.2 100 mg · wk 2 · n 207 · Phase 3 · secondary NCT02886728
  • -1.0 vs -0.9 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  • -0.7 vs -0.4 wk 12 · n 21 · Phase 2 · secondary NCT02885181

Modified Sharp score, change

baricitinib
0.3 vs 0.8−0.5 vs placebowk 24 · n 470NCT01710358
2 other results
  • 0.4 vs 0.6 wk 24 · n 152 · Phase 3 · secondary NCT01711359
  • 0.3 vs 0.6 wk 24 · n 198 · Phase 3 · secondary NCT01711359
filgotinib
0.1 vs 0.4−0.2 vs placebo200 mg · wk 24 · n 467NCT02889796
9 other results
  • 0.2 vs 0.9 200 mg · wk 52 · n 468 · Phase 3 · secondary NCT02889796
  • 0.2 vs 0.4 100 mg · wk 24 · n 471 · Phase 3 · secondary NCT02889796
  • 0.5 vs 0.9 100 mg · wk 52 · n 472 · Phase 3 · secondary NCT02889796
  • -0.0 vs 0.5 200 mg · wk 24 · n 210 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 210 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 200 mg · wk 24 · n 416 · Phase 3 · secondary NCT02886728
  • 0.3 vs 0.8 200 mg · wk 52 · n 416 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.5 100 mg · wk 24 · n 207 · Phase 3 · secondary NCT02886728
  • 0.2 vs 0.8 100 mg · wk 52 · n 207 · Phase 3 · secondary NCT02886728
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety

Coverage. baricitinib: 9 of 9 rows · filgotinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricbaricitinib
Rows use multiple source trials
filgotinib
Rows use multiple source trials
Boolean Remission
responder rate · % of participants
12.1% (n=487) vs 2.7% (n=488) placebo @ 24wka,b,c
NCT01710358 · Phase 3
4 other source trials
18.9% (n=159) vs 8.6% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3
16.3% (n=215) vs 8.6% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3 · combination
4% (n=174) vs 1.1% (n=176) placebo @ 24wk2 mg
NCT01721044 · Phase 3
6.8% (n=177) vs 1.1% (n=176) placebo @ 24wk4 mg
NCT01721044 · Phase 3
11.6% (n=86) vs 1.2% (n=86) placebo @ 24wk200 mg QDd,a,b,c
NCT01888874 · Phase 2 · registry result, not featured evidence
show 5 more doses
19% (n=84) vs 1.2% (n=86) placebo @ 24wk100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2% (n=85) vs 1.2% (n=86) placebo @ 24wk100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5% (n=85) vs 1.2% (n=86) placebo @ 24wk50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
11% (n=82) vs 1.2% (n=86) placebo @ 24wk50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.8% (n=86) vs 1.2% (n=86) placebo @ 24wk25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
CDAI
absolute change · score
-26.44 vs NA placebo score @ 52wkb
NCT01710358 · Phase 3
2 other source trials
-28.94 vs -21.95 Methotrexate score @ 52wk
NCT01711359 · Phase 3
-30.72 vs -21.95 Methotrexate score @ 52wk
NCT01711359 · Phase 3 · combination
-33.6 vs -31.2 MTX score @ 52wk200 mgd,b
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
-33.8 vs -31.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-31.9 vs -31.2 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
DAS28-CRP
absolute change · score
-2.74 vs -2.01 Methotrexate score @ 24wkd,b
NCT01711359 · Phase 3
show 1 more dose
-2.82 vs -2.01 Methotrexate score @ 24wk
NCT01711359 · Phase 3 · combination
-2.9 vs -2.1 placebo score @ 24wk200 mgd,b
NCT02873936 · Phase 3
show 1 more dose
-2.6 vs -2.1 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
FACIT-Fatigue
absolute change · score
10.8 vs NA placebo score @ 52wkb
NCT01710358 · Phase 3
2 other source trials
11.3 vs 9.1 Methotrexate score @ 52wk
NCT01711359 · Phase 3
12.6 vs 9.1 Methotrexate score @ 52wk
NCT01711359 · Phase 3 · combination
11.5 vs 11.3 MTX score @ 52wk200 mgd,b
NCT02886728 · Phase 3 · monotherapy
show 2 more doses
11.7 vs 11.3 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
11.9 vs 11.3 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
SDAI
absolute change · score
-23.78 vs -14.55 placebo score @ 24wk4 mgd,b,c
NCT01721057 · Phase 3
show 1 more dose
-21.87 vs -14.55 placebo score @ 24wk2 mg
NCT01721057 · Phase 3
-32.1 vs -24.9 placebo score @ 24wk200 mgd,b,c
NCT02873936 · Phase 3
show 1 more dose
-28.8 vs -24.9 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
Dropout rate
5.9%Baricitinibe
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
15%Baricitinib
NCT01711359 · Phase 3
19.5%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
6.2%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
10.1%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
8.3%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
9.8%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
51.7%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
51.1%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
55.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
60.8%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
33.7%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
94.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
75.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
70.2%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
95.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
100%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
76.9%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
72.8%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
8.8%200 mge
NCT02873936 · Phase 3
show 26 more results
15%100 mg
NCT02873936 · Phase 3
17.1%200 mg
NCT02886728 · Phase 3 · monotherapy
17.3%200 mg
NCT02886728 · Phase 3 · combination
15.5%100 mg
NCT02886728 · Phase 3 · combination
11.1%200 mg
NCT02889796 · Phase 3
12.1%100 mg
NCT02889796 · Phase 3
52.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
53.7%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
61.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
0%Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
67.6%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
66.5%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
4.3%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
6.9%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
7%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
8.2%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
5.9%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
7.3%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
10.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.7%Baricitinibe
NCT01710358 · Phase 3
show 43 more results
—Baricitinib Follow-up
NCT01710358 · Phase 3
—Baricitinib Treatment A
NCT01710358 · Phase 3
—BaricitinibTreatment B
NCT01710358 · Phase 3
6.3%Baricitinib
NCT01711359 · Phase 3
11.2%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
—Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
—Baricitinib - Follow-up
NCT01711359 · Phase 3
1.4%4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—4 mg
NCT02265705 · Phase 3
—Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
—4 mg
NCT01469013 · Phase 2
—2 mg
NCT01469013 · Phase 2
—8 mg
NCT01469013 · Phase 2
—1 mg
NCT01469013 · Phase 2
—4 mg
NCT01721057 · Phase 3
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
4.4%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
5.6%4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
—4 mg
NCT01721044 · Phase 3
4%2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
13.5%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
12.6%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
8.3%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
5.7%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
6%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
12.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
21.8%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
18.1%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
11.5%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
10.9%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
14.5%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
16.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
2%200 mge
NCT02873936 · Phase 3
show 26 more results
3.3%100 mg
NCT02873936 · Phase 3
2.4%200 mg
NCT02886728 · Phase 3 · monotherapy
3.1%200 mg
NCT02886728 · Phase 3 · combination
2.4%100 mg
NCT02886728 · Phase 3 · combination
3.6%200 mg
NCT02889796 · Phase 3
1.7%100 mg
NCT02889796 · Phase 3
12.3%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
13.4%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
14%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
12.2%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
33.2%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
42.6%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
1.4%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
1.2%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
1.2%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
2.4%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.5%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Serious AEs
—Baricitinibe
NCT01710358 · Phase 3
show 43 more results
0%Baricitinib Follow-up
NCT01710358 · Phase 3
5.3%Baricitinib Treatment A
NCT01710358 · Phase 3
3.8%BaricitinibTreatment B
NCT01710358 · Phase 3
7.5%Baricitinib
NCT01711359 · Phase 3
7.9%Baricitinib + MTX
NCT01711359 · Phase 3 · combination
0%Baricitinib + MTX - Follow-up
NCT01711359 · Phase 3 · combination
0%Baricitinib - Follow-up
NCT01711359 · Phase 3
2.8%4 mg
NCT02265705 · Phase 3
1.7%4 mg
NCT02265705 · Phase 3
2.5%4 mg
NCT02265705 · Phase 3
9.5%Placebo to Baricitinib Treatment P
NCT02265705 · Phase 3
0%4 mg
NCT01469013 · Phase 2
4.2%2 mg
NCT01469013 · Phase 2
4.2%8 mg
NCT01469013 · Phase 2
0%1 mg
NCT01469013 · Phase 2
5.3%4 mg
NCT01721057 · Phase 3
—4 mg
NCT01721057 · Phase 3
4.5%4 mg
NCT01721057 · Phase 3
2.6%2 mg
NCT01721057 · Phase 3
—2 mg
NCT01721057 · Phase 3
0%2 mg
NCT01721057 · Phase 3
—4 mg
NCT01721044 · Phase 3
0%4 mg
NCT01721044 · Phase 3
10.7%4 mg
NCT01721044 · Phase 3
—2 mg
NCT01721044 · Phase 3
11.1%2 mg
NCT01721044 · Phase 3
4.6%2 mg
NCT01721044 · Phase 3
31.3%4 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
29.5%2 mg
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
23.7%4 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
22.9%2 mg
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
20%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
30%4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—4 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
37.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
27.7%2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
—2 mg
NCT01885078 · Phase 3 · registry result, not featured evidence
4.1%200 mge
NCT02873936 · Phase 3
show 26 more results
5.2%100 mg
NCT02873936 · Phase 3
8.1%200 mg
NCT02886728 · Phase 3 · monotherapy
6.3%200 mg
NCT02886728 · Phase 3 · combination
6.3%100 mg
NCT02886728 · Phase 3 · combination
7.4%200 mg
NCT02889796 · Phase 3
8.3%100 mg
NCT02889796 · Phase 3
24.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
22.1%200 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
24.6%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
25.9%100 mg
NCT03025308 · Phase 3 · registry result, not featured evidence
3.7%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
12.8%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
14.3%200 mg
NCT03926195 · Phase 2 · registry result, not featured evidence
—Filgonitib
NCT03926195 · Phase 2 · registry result, not featured evidence
16.9%Filgotinib Darwin 1
NCT02065700 · Phase 2 · registry result, not featured evidence
19.8%Filgotinib Darwin 2
NCT02065700 · Phase 2 · registry result, not featured evidence
0%
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
4.3%200 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
3.5%100 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.8%50 mg QD
NCT01894516 · Phase 2 · registry result, not featured evidence
2.3%200 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
3.6%100 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
3.4%100 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
0%50 mg QD
NCT01888874 · Phase 2 · registry result, not featured evidence
2.3%25 mg BID
NCT01888874 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
e
alanine aminotransferase increased 0% (placebo 0%)
anaemia 0% (placebo 0%)
back pain 0% (placebo 0%)
NCT01710358 · Phase 3
show 30 more results
nasopharyngitis 7.6% (placebo 6.1%)
urinary tract infection 4.3% (placebo 0%)
bronchitis 3.9% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 5.7% (placebo 6.1%)
upper respiratory tract infection 3.1% (placebo 0%)
bronchitis 2.8% (placebo 0%)
NCT01710358 · Phase 3
nasopharyngitis 10.1%
upper respiratory tract infection 7.5%
gastroenteritis 6.3%
NCT01711359 · Phase 3
nasopharyngitis 9.8%
nausea 9.3%
upper respiratory tract infection 7.4%
NCT01711359 · Phase 3 · combination
abdominal discomfort 0%
abdominal pain upper 0%
alanine aminotransferase increased 0%
NCT01711359 · Phase 3 · combination
constipation 6.7%
eczema asteatotic 6.7%
miliaria 6.7%
NCT01711359 · Phase 3
4 mg
upper respiratory tract infection 19.3% (placebo 0%)
hyperlipidaemia 11% (placebo 0%)
urinary tract infection 9% (placebo 0%)
NCT02265705 · Phase 3
4 mg
arthralgia 5.2% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT02265705 · Phase 3
4 mg
upper respiratory tract infection 9.2% (placebo 0%)
hyperlipidaemia 7.5% (placebo 0%)
benign prostatic hyperplasia 7.1% (placebo 0%)
NCT02265705 · Phase 3
blood creatine phosphokinase increased 6.8% (placebo 0%)
upper respiratory tract infection 6.8% (placebo 0%)
nasopharyngitis 5.4% (placebo 0%)
NCT02265705 · Phase 3
4 mg
blood creatine phosphokinase increased 8.3% (placebo 4.1%)
liver function test abnormal 8.3% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
NCT01469013 · Phase 2
2 mg
hepatic function abnormal 12.5% (placebo 0%)
nasopharyngitis 8.3% (placebo 12.2%)
cystitis 4.2% (placebo 4.1%)
NCT01469013 · Phase 2
8 mg
blood creatine phosphokinase increased 12.5% (placebo 4.1%)
hepatic function abnormal 12.5% (placebo 0%)
hypercholesterolaemia 12.5% (placebo 0%)
NCT01469013 · Phase 2
1 mg
nasopharyngitis 8.3% (placebo 12.2%)
anaemia 4.2% (placebo 0%)
chronic sinusitis 4.2% (placebo 0%)
NCT01469013 · Phase 2
4 mg
upper respiratory tract infection 10.6% (placebo 0%)
nasopharyngitis 7.9% (placebo 0%)
blood creatine phosphokinase increased 6.6% (placebo 5.9%)
NCT01721057 · Phase 3
4 mg
cough 4.5% (placebo 0%)
dyspnoea 4.5% (placebo 0%)
gastritis 4.5% (placebo 0%)
NCT01721057 · Phase 3
2 mg
headache 6.6% (placebo 0%)
upper respiratory tract infection 6.1% (placebo 0%)
urinary tract infection 5.2% (placebo 0%)
NCT01721057 · Phase 3
2 mg
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
acne 0% (placebo 0%)
NCT01721057 · Phase 3
4 mg
cervicitis 5.6% (placebo 0%)
abdominal pain 0% (placebo 0%)
abdominal pain upper 0% (placebo 0%)
NCT01721044 · Phase 3
4 mg
headache 6.8% (placebo 0%)
bronchitis 5.6% (placebo 0%)
nausea 5.6% (placebo 0%)
NCT01721044 · Phase 3
2 mg
cellulitis 11.1% (placebo 0%)
insomnia 11.1% (placebo 0%)
lymphopenia 11.1% (placebo 0%)
NCT01721044 · Phase 3
2 mg
headache 9.8% (placebo 0%)
upper respiratory tract infection 8.6% (placebo 0%)
nasopharyngitis 6.9% (placebo 5.3%)
NCT01721044 · Phase 3
4 mg
covid-19 23.3%
nasopharyngitis 13.8%
urinary tract infection 11.4%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 20.8%
nasopharyngitis 11.6%
urinary tract infection 11.3%
NCT03915964 · Phase 4 · registry result, not featured evidence · pooled
4 mg
covid-19 8.4%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
2 mg
covid-19 8.8%
NCT04086745 · Phase 4 · registry result, not featured evidence · pooled
4 mg
bronchitis 11.3%
nasopharyngitis 11.3%
upper respiratory tract infection 10.9%
NCT01885078 · Phase 3 · registry result, not featured evidence
4 mg
bronchitis 10.9%
nasopharyngitis 9.8%
influenza 9.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
upper respiratory tract infection 19.5%
urinary tract infection 17.8%
bronchitis 16.2%
NCT01885078 · Phase 3 · registry result, not featured evidence
2 mg
nasopharyngitis 9.1%
upper respiratory tract infection 7.8%
bronchitis 7.4%
NCT01885078 · Phase 3 · registry result, not featured evidence
200 mge
nasopharyngitis 10.2% (placebo 4.7%)
bronchitis 5.4% (placebo 5.4%)
headache 5.4% (placebo 1.4%)
NCT02873936 · Phase 3
show 25 more results
100 mg
headache 5.9% (placebo 1.4%)
nasopharyngitis 5.9% (placebo 4.7%)
upper respiratory tract infection 5.9% (placebo 4.1%)
NCT02873936 · Phase 3
200 mg
nasopharyngitis 8.1%
hypertension 7.1%
nausea 7.1%
NCT02886728 · Phase 3 · monotherapy
200 mg
nausea 12.3%
upper respiratory tract infection 10.1%
alanine aminotransferase increased 5.5%
NCT02886728 · Phase 3 · combination
100 mg
nausea 16.9%
nasopharyngitis 8.2%
alopecia 7.2%
NCT02886728 · Phase 3 · combination
200 mg
nasopharyngitis 9.1% (placebo 5.3%)
upper respiratory tract infection 8.6% (placebo 2.9%)
nausea 5.5% (placebo 1.5%)
NCT02889796 · Phase 3
100 mg
upper respiratory tract infection 10.2% (placebo 2.9%)
nasopharyngitis 10% (placebo 5.3%)
alanine aminotransferase increased 5.2% (placebo 2.3%)
NCT02889796 · Phase 3
200 mg
covid-19 18.3%
nasopharyngitis 13.1%
upper respiratory tract infection 11%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
covid-19 17.3%
upper respiratory tract infection 13.1%
rheumatoid arthritis 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 15.3%
nasopharyngitis 15.1%
rheumatoid arthritis 13.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
100 mg
covid-19 18.5%
rheumatoid arthritis 12.2%
upper respiratory tract infection 11.9%
NCT03025308 · Phase 3 · registry result, not featured evidence
200 mg
nasopharyngitis 7.4% (placebo 7.3%)
dyslipidaemia 3.7% (placebo 0%)
headache 3.7% (placebo 1.8%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
covid-19 15.4% (placebo 0%)
ankylosing spondylitis 7.7% (placebo 0%)
latent tuberculosis 7.7% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 57.1% (placebo 7.3%)
covid-19 42.9% (placebo 0%)
alanine aminotransferase increased 14.3% (placebo 0%)
NCT03926195 · Phase 2 · registry result, not featured evidence
hypertension 15.1%
urinary tract infection 14.5%
nasopharyngitis 14.1%
NCT02065700 · Phase 2 · registry result, not featured evidence
mycobacterium tuberculosis complex test positive 16.5%
upper respiratory tract infection 15.3%
hypercholesterolaemia 12.4%
NCT02065700 · Phase 2 · registry result, not featured evidence
asthenia 9.5% (placebo 0%)
blood creatine phosphokinase increased 4.8% (placebo 0%)
dyspepsia 4.8% (placebo 0%)
NCT02885181 · Phase 2 · registry result, not featured evidence · background therapy
200 mg QD
anaemia 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 2.8%)
urinary tract infection 5.8% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
100 mg QD
urinary tract infection 8.2% (placebo 1.4%)
hypercholesterolaemia 5.9% (placebo 4.2%)
hypertriglyceridaemia 5.9% (placebo 1.4%)
NCT01894516 · Phase 2 · registry result, not featured evidence
50 mg QD
headache 5.6% (placebo 1.4%)
hypercholesterolaemia 5.6% (placebo 4.2%)
hypertension 4.2% (placebo 5.6%)
NCT01894516 · Phase 2 · registry result, not featured evidence
200 mg QD
headache 7% (placebo 4.7%)
hypercholesterolaemia 5.8% (placebo 0%)
hypertension 4.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg BID
hypercholesterolaemia 4.8% (placebo 0%)
nasopharyngitis 4.8% (placebo 4.7%)
headache 2.4% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence
100 mg QD
hypertension 5% (placebo 2.3%)
nasopharyngitis 2.5% (placebo 4.7%)
upper respiratory tract infection 1.7% (placebo 1.2%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg BID
upper respiratory tract infection 5.1% (placebo 1.2%)
vomiting 5.1% (placebo 1.2%)
hypertension 3.4% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
50 mg QD
nasopharyngitis 9.8% (placebo 4.7%)
nausea 8.5% (placebo 3.5%)
hypertension 3.7% (placebo 2.3%)
NCT01888874 · Phase 2 · registry result, not featured evidence
25 mg BID
headache 7% (placebo 4.7%)
gastroenteritis 5.8% (placebo 0%)
nasopharyngitis 4.7% (placebo 4.7%)
NCT01888874 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

baricitinib

ACR50 45% (n=487) vs 16.8% (n=488) placebo @ 12wk
responder rate · % of participants
ACR50 Week 12
NCT01710358 · Phase 3
ACR50 50.5% (n=487) vs 19.3% (n=488) placebo @ 24wk
responder rate · % of participants
ACR50 Week 24
NCT01710358 · Phase 3
ACR50 55.9% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR50 Week 52
NCT01710358 · Phase 3
ACR70 18.9% (n=487) vs 4.7% (n=488) placebo @ 12wk
responder rate · % of participants
ACR70 Week 12
NCT01710358 · Phase 3
ACR70 29.8% (n=487) vs 8% (n=488) placebo @ 24wk
responder rate · % of participants
ACR70 Week 24
NCT01710358 · Phase 3
ACR70 37.2% (n=487) vs NA placebo @ 52wk
responder rate · % of participants
ACR70 Week 52
NCT01710358 · Phase 3
SDAI Remission 17% (n=24) vs 8% (n=49) placebo @ 12wk4 mg
responder rate · % of participants
NCT01469013 · Phase 2
show 13 more results
8.8% (n=227) vs 0.9% (n=228) placebo @ 12wk4 mg
NCT01721057 · Phase 3
5.1% (n=177) vs 1.7% (n=176) placebo @ 12wk4 mg
NCT01721044 · Phase 3
29% (n=24) vs 8% (n=49) placebo @ 12wk2 mg
NCT01469013 · Phase 2
9.2% (n=229) vs 0.9% (n=228) placebo @ 12wk2 mg
NCT01721057 · Phase 3
2.3% (n=174) vs 1.7% (n=176) placebo @ 12wk2 mg
NCT01721044 · Phase 3
17% (n=24) vs 8% (n=49) placebo @ 12wk8 mg
NCT01469013 · Phase 2
4% (n=24) vs 8% (n=49) placebo @ 12wk1 mg
NCT01469013 · Phase 2
8.4% (n=487) vs 1.8% (n=488) placebo @ 12wk
NCT01710358 · Phase 3
16% (n=487) vs 3.1% (n=488) placebo @ 24wk
NCT01710358 · Phase 3
22.6% (n=487) vs NA placebo @ 52wk
NCT01710358 · Phase 3
22% (n=159) vs 10.5% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3
22.8% (n=215) vs 10.5% (n=210) Methotrexate @ 24wk
NCT01711359 · Phase 3 · combination
1.4% (n=145) vs 0% (n=145) placebo @ 12wk*
NCT02265705 · Phase 3 · converted to % from 2 Participants as posted
SF-36 Mental Component Summary 3.3 vs 3.2 placebo score @ 12wk
absolute change · score
MCS Week 12
NCT01710358 · Phase 3
SF-36 Mental Component Summary 3.8 vs 2.2 placebo score @ 24wk
absolute change · score
MCS Week 24
NCT01710358 · Phase 3
SF-36 Mental Component Summary 4 vs NA placebo score @ 52wk
absolute change · score
MCS Week 52
NCT01710358 · Phase 3
SF-36 Physical Component Summary 8.9 vs 4.3 placebo score @ 12wk
absolute change · score
PCS Week 12
NCT01710358 · Phase 3
SF-36 Physical Component Summary 9.9 vs 4.6 placebo score @ 24wk
absolute change · score
PCS Week 24
NCT01710358 · Phase 3

+ 75 further endpoints in the CSV export.

filgotinib

DAS Low Disease Activity 40.8% (n=147) vs 15.5% (n=148) placebo @ 12wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 29 more results
21.8% (n=147) vs 9.5% (n=148) placebo @ 4wk200 mg
NCT02873936 · Phase 3
48.3% (n=147) vs 20.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
31.9% (n=210) vs 12% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
48.1% (n=210) vs 28.6% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
60% (n=210) vs 46.2% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
65.7% (n=210) vs 47.6% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
49.7% (n=475) vs 23.4% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
13.1% (n=475) vs 3.6% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
25.5% (n=475) vs 9.3% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
60.6% (n=475) vs 33.7% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
67.4% (n=475) vs 74.7% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
68.2% (n=475) vs 69.5% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
37.3% (n=153) vs 15.5% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
22.2% (n=153) vs 9.5% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
37.9% (n=153) vs 20.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
38.8% (n=480) vs 23.4% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
8.1% (n=480) vs 3.6% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
20.4% (n=480) vs 9.3% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
53.1% (n=480) vs 33.7% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
60.2% (n=480) vs 74.7% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
62.1% (n=480) vs 69.5% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
30.8% (n=416) vs 12% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
55.8% (n=416) vs 28.6% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
68.8% (n=416) vs 46.2% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
69% (n=416) vs 47.6% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
23.7% (n=207) vs 12% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
50.2% (n=207) vs 28.6% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
62.8% (n=207) vs 46.2% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
59.9% (n=207) vs 47.6% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
SF-36 PCS 7.6 vs 3.6 placebo score @ 12wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 30 more results
5.1 vs 2.5 placebo score @ 4wk200 mg
NCT02873936 · Phase 3
9.4 vs 6.6 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
10.4 vs 9.7 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
5.9 vs 3.8 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
8.9 vs 7.6 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.2 vs 11.3 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
11.9 vs 11.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
9.2 vs 5.8 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
5.6 vs 3.1 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
10.4 vs 7.7 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
11.6 vs 12.9 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
12 vs 13 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
6.8 vs 3.6 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
4.5 vs 2.5 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
9 vs 6.6 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
8.5 vs 5.8 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
4.6 vs 3.1 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
10.3 vs 7.7 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
11 vs 12.9 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
11.5 vs 13 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
12.3 vs 9.7 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
6.8 vs 3.8 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
11.2 vs 7.6 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
12.4 vs 11.3 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
13.4 vs 11.2 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
11.1 vs 9.7 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
5.3 vs 3.8 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
9.1 vs 7.6 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
11.7 vs 11.3 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
12 vs 11.2 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
DAS28 (CRP) Remission 30.6% (n=147) vs 12.2% (n=148) placebo @ 24wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 35 more results
10.2% (n=147) vs 2.7% (n=148) placebo @ 4wk200 mg
NCT02873936 · Phase 3
22.4% (n=147) vs 8.1% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
42.4% (n=210) vs 29.1% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
10% (n=210) vs 1% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
19.5% (n=210) vs 4.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
29.5% (n=210) vs 17.1% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
43.3% (n=210) vs 34.4% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
46.2% (n=210) vs 31.5% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
34.1% (n=475) vs 9.3% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
5.1% (n=475) vs 0.6% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
13.7% (n=475) vs 2.9% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
48.4% (n=475) vs 16.2% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
50.3% (n=475) vs 52.1% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
54.5% (n=475) vs 50.5% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
26.1% (n=153) vs 12.2% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
11.8% (n=153) vs 2.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
25.5% (n=153) vs 8.1% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
23.8% (n=480) vs 9.3% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
1.7% (n=480) vs 0.6% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
8.8% (n=480) vs 2.9% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
35.2% (n=480) vs 16.2% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
42.9% (n=480) vs 52.1% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
44.8% (n=480) vs 50.5% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
54.1% (n=416) vs 29.1% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
7.2% (n=416) vs 1% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
16.6% (n=416) vs 4.8% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
39.7% (n=416) vs 17.1% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
52.6% (n=416) vs 34.4% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
53.4% (n=416) vs 31.5% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
42.5% (n=207) vs 29.1% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
4.3% (n=207) vs 1% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
15% (n=207) vs 4.8% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
31.9% (n=207) vs 17.1% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
42% (n=207) vs 34.4% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
43% (n=207) vs 31.5% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Tender Joint Count -13 vs -8 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-18 vs -12 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-22 vs -17 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-22 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-23 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-8 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-17 vs -13 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-20 vs -17 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-11 vs -8 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-16 vs -12 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-7 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-10 vs -8 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-15 vs -13 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-19 vs -17 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-20 vs -21 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-21 vs -21 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-9 vs -5 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -8 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-18 vs -15 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-22 vs -21 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-8 vs -5 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -8 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-17 vs -15 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-20 vs -19 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-21 vs -21 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Swollen Joint Count -10 vs -7 placebo count @ 4wk200 mg
absolute change · count
NCT02873936 · Phase 3
show 35 more results
-12 vs -8 placebo count @ 12wk200 mg
NCT02873936 · Phase 3
-14 vs -12 placebo count @ 24wk200 mg
NCT02873936 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-15 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-16 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-6 vs -5 placebo count @ 2wk200 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk200 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk200 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 36wk200 mg
NCT02889796 · Phase 3
-14 vs -14 placebo count @ 52wk200 mg
NCT02889796 · Phase 3
-7 vs -7 placebo count @ 4wk100 mg
NCT02873936 · Phase 3
-10 vs -8 placebo count @ 12wk100 mg
NCT02873936 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02873936 · Phase 3
-5 vs -5 placebo count @ 2wk100 mg
NCT02889796 · Phase 3
-8 vs -6 placebo count @ 4wk100 mg
NCT02889796 · Phase 3
-11 vs -10 placebo count @ 12wk100 mg
NCT02889796 · Phase 3
-13 vs -12 placebo count @ 24wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 36wk100 mg
NCT02889796 · Phase 3
-13 vs -14 placebo count @ 52wk100 mg
NCT02889796 · Phase 3
-7 vs -4 MTX count @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -11 MTX count @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-15 vs -14 MTX count @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-6 vs -4 MTX count @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-9 vs -6 MTX count @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-12 vs -11 MTX count @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -13 MTX count @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-14 vs -14 MTX count @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Patient Global Assessment -21 vs -10 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 35 more results
-31 vs -14 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
-38 vs -24 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-14 vs -7 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-22 vs -14 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-32 vs -25 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-38 vs -34 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-39 vs -38 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-43 vs -38 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-16 vs -8 placebo score @ 2wk200 mg
NCT02889796 · Phase 3
-22 vs -13 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
-33 vs -21 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
-39 vs -31 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
-42 vs -45 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
-44 vs -45 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
-20 vs -10 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-34 vs -24 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-11 vs -8 placebo score @ 2wk100 mg
NCT02889796 · Phase 3
-16 vs -13 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
-28 vs -21 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
-36 vs -31 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
-39 vs -45 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
-41 vs -45 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
-17 vs -7 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-26 vs -14 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-37 vs -25 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-42 vs -34 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-43 vs -38 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-45 vs -38 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-13 vs -7 MTX score @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-20 vs -14 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-30 vs -25 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-36 vs -34 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-39 vs -38 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-41 vs -38 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Physician Global Assessment -32 vs -19 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 35 more results
-45 vs -28 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
-53 vs -41 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-23 vs -15 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-30 vs -23 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-42 vs -38 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-49 vs -46 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-52 vs -51 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-55 vs -51 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-20 vs -13 placebo score @ 2wk200 mg
NCT02889796 · Phase 3
-28 vs -20 placebo score @ 4wk200 mg
NCT02889796 · Phase 3
-41 vs -34 placebo score @ 12wk200 mg
NCT02889796 · Phase 3
-48 vs -42 placebo score @ 24wk200 mg
NCT02889796 · Phase 3
-51 vs -53 placebo score @ 36wk200 mg
NCT02889796 · Phase 3
-53 vs -54 placebo score @ 52wk200 mg
NCT02889796 · Phase 3
-30 vs -19 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-41 vs -28 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-45 vs -41 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
-18 vs -13 placebo score @ 2wk100 mg
NCT02889796 · Phase 3
-26 vs -20 placebo score @ 4wk100 mg
NCT02889796 · Phase 3
-39 vs -34 placebo score @ 12wk100 mg
NCT02889796 · Phase 3
-46 vs -42 placebo score @ 24wk100 mg
NCT02889796 · Phase 3
-49 vs -53 placebo score @ 36wk100 mg
NCT02889796 · Phase 3
-50 vs -54 placebo score @ 52wk100 mg
NCT02889796 · Phase 3
-24 vs -15 MTX score @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-34 vs -23 MTX score @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-47 vs -38 MTX score @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-51 vs -46 MTX score @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-53 vs -51 MTX score @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-56 vs -51 MTX score @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-21 vs -15 MTX score @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-32 vs -23 MTX score @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-43 vs -38 MTX score @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-51 vs -46 MTX score @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-51 vs -51 MTX score @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-54 vs -51 MTX score @ 52wk100 mg
NCT02886728 · Phase 3 · combination
Patient Assessment of Arthritis Pain -22 vs -8 placebo score @ 4wk200 mg
absolute change · score
NCT02873936 · Phase 3
show 5 more results
-30 vs -14 placebo score @ 12wk200 mg
NCT02873936 · Phase 3
-37 vs -24 placebo score @ 24wk200 mg
NCT02873936 · Phase 3
-20 vs -8 placebo score @ 4wk100 mg
NCT02873936 · Phase 3
-27 vs -14 placebo score @ 12wk100 mg
NCT02873936 · Phase 3
-35 vs -24 placebo score @ 24wk100 mg
NCT02873936 · Phase 3
CRP Change -9.55 vs 1.04 placebo mg @ 4wk200 mg
absolute change · mg
NCT02873936 · Phase 3
show 35 more results
-11.86 vs 0.57 placebo mg @ 12wk200 mg
NCT02873936 · Phase 3
-10.87 vs -1.5 placebo mg @ 24wk200 mg
NCT02873936 · Phase 3
-10.97 vs -0.99 MTX mg @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
-10.95 vs -3.18 MTX mg @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
-12.04 vs -7.23 MTX mg @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
-12.66 vs -7.47 MTX mg @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
-11.52 vs -8.74 MTX mg @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
-12.29 vs -7.96 MTX mg @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
-10.85 vs -0.07 placebo mg @ 2wk200 mg
NCT02889796 · Phase 3
-9.99 vs -1.12 placebo mg @ 4wk200 mg
NCT02889796 · Phase 3
-11 vs -3.26 placebo mg @ 12wk200 mg
NCT02889796 · Phase 3
-11.84 vs -4 placebo mg @ 24wk200 mg
NCT02889796 · Phase 3
-11.51 vs -12.12 placebo mg @ 36wk200 mg
NCT02889796 · Phase 3
-12.19 vs -11.43 placebo mg @ 52wk200 mg
NCT02889796 · Phase 3
-12.15 vs 1.04 placebo mg @ 4wk100 mg
NCT02873936 · Phase 3
-12.02 vs 0.57 placebo mg @ 12wk100 mg
NCT02873936 · Phase 3
-11.12 vs -1.5 placebo mg @ 24wk100 mg
NCT02873936 · Phase 3
-7.67 vs -0.07 placebo mg @ 2wk100 mg
NCT02889796 · Phase 3
-8.44 vs -1.12 placebo mg @ 4wk100 mg
NCT02889796 · Phase 3
-9.55 vs -3.26 placebo mg @ 12wk100 mg
NCT02889796 · Phase 3
-10.54 vs -4 placebo mg @ 24wk100 mg
NCT02889796 · Phase 3
-10.72 vs -12.12 placebo mg @ 36wk100 mg
NCT02889796 · Phase 3
-11.27 vs -11.43 placebo mg @ 52wk100 mg
NCT02889796 · Phase 3
-12.89 vs -0.99 MTX mg @ 2wk200 mg
NCT02886728 · Phase 3 · combination
-13.79 vs -3.18 MTX mg @ 4wk200 mg
NCT02886728 · Phase 3 · combination
-13.77 vs -7.23 MTX mg @ 12wk200 mg
NCT02886728 · Phase 3 · combination
-13.43 vs -7.47 MTX mg @ 24wk200 mg
NCT02886728 · Phase 3 · combination
-12.99 vs -8.74 MTX mg @ 36wk200 mg
NCT02886728 · Phase 3 · combination
-13.84 vs -7.96 MTX mg @ 52wk200 mg
NCT02886728 · Phase 3 · combination
-9.4 vs -0.99 MTX mg @ 2wk100 mg
NCT02886728 · Phase 3 · combination
-11.53 vs -3.18 MTX mg @ 4wk100 mg
NCT02886728 · Phase 3 · combination
-11.02 vs -7.23 MTX mg @ 12wk100 mg
NCT02886728 · Phase 3 · combination
-10.85 vs -7.47 MTX mg @ 24wk100 mg
NCT02886728 · Phase 3 · combination
-12.64 vs -8.74 MTX mg @ 36wk100 mg
NCT02886728 · Phase 3 · combination
-11.61 vs -7.96 MTX mg @ 52wk100 mg
NCT02886728 · Phase 3 · combination
HAQ Improvement 60.4% (n=147) vs 40.3% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
NCT02873936 · Phase 3
show 23 more results
66.7% (n=147) vs 44.4% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
68.8% (n=147) vs 35.4% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
53.9% (n=210) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · monotherapy
68.6% (n=210) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · monotherapy
74% (n=210) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · monotherapy
77% (n=210) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · monotherapy
73.5% (n=210) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · monotherapy
70.6% (n=210) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · monotherapy
54.7% (n=153) vs 40.3% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
66.2% (n=153) vs 44.4% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
54.1% (n=153) vs 35.4% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
61.9% (n=416) vs 42.2% (n=416) MTX @ 2wk200 mg
NCT02886728 · Phase 3 · combination
72.4% (n=416) vs 53.9% (n=416) MTX @ 4wk200 mg
NCT02886728 · Phase 3 · combination
80.3% (n=416) vs 69.8% (n=416) MTX @ 12wk200 mg
NCT02886728 · Phase 3 · combination
76.6% (n=416) vs 73.9% (n=416) MTX @ 24wk200 mg
NCT02886728 · Phase 3 · combination
73.4% (n=416) vs 67.1% (n=416) MTX @ 36wk200 mg
NCT02886728 · Phase 3 · combination
70.9% (n=416) vs 61% (n=416) MTX @ 52wk200 mg
NCT02886728 · Phase 3 · combination
58.5% (n=207) vs 42.2% (n=416) MTX @ 2wk100 mg
NCT02886728 · Phase 3 · combination
61% (n=207) vs 53.9% (n=416) MTX @ 4wk100 mg
NCT02886728 · Phase 3 · combination
74.5% (n=207) vs 69.8% (n=416) MTX @ 12wk100 mg
NCT02886728 · Phase 3 · combination
78.5% (n=207) vs 73.9% (n=416) MTX @ 24wk100 mg
NCT02886728 · Phase 3 · combination
76.5% (n=207) vs 67.1% (n=416) MTX @ 36wk100 mg
NCT02886728 · Phase 3 · combination
71.5% (n=207) vs 61% (n=416) MTX @ 52wk100 mg
NCT02886728 · Phase 3 · combination
ACR-N 26.9% (n=147) vs 13.7% (n=148) placebo @ 4wk200 mg
absolute value · percentage points
NCT02873936 · Phase 3
show 17 more results
43.4% (n=147) vs 19.7% (n=148) placebo @ 12wk200 mg
NCT02873936 · Phase 3
53.5% (n=147) vs 31.9% (n=148) placebo @ 24wk200 mg
NCT02873936 · Phase 3
18.3% (n=475) vs 8% (n=475) placebo @ 2wk200 mg
NCT02889796 · Phase 3
27.4% (n=475) vs 15.1% (n=475) placebo @ 4wk200 mg
NCT02889796 · Phase 3
46.8% (n=475) vs 28.1% (n=475) placebo @ 12wk200 mg
NCT02889796 · Phase 3
58.8% (n=475) vs 42.6% (n=475) placebo @ 24wk200 mg
NCT02889796 · Phase 3
62.5% (n=475) vs 63.2% (n=190) placebo @ 36wk200 mg
NCT02889796 · Phase 3
66% (n=475) vs 63.8% (n=190) placebo @ 52wk200 mg
NCT02889796 · Phase 3
25.8% (n=153) vs 13.7% (n=148) placebo @ 4wk100 mg
NCT02873936 · Phase 3
37.1% (n=153) vs 19.7% (n=148) placebo @ 12wk100 mg
NCT02873936 · Phase 3
45.5% (n=153) vs 31.9% (n=148) placebo @ 24wk100 mg
NCT02873936 · Phase 3
14% (n=480) vs 8% (n=475) placebo @ 2wk100 mg
NCT02889796 · Phase 3
23% (n=480) vs 15.1% (n=475) placebo @ 4wk100 mg
NCT02889796 · Phase 3
40.6% (n=480) vs 28.1% (n=475) placebo @ 12wk100 mg
NCT02889796 · Phase 3
55.4% (n=480) vs 42.6% (n=475) placebo @ 24wk100 mg
NCT02889796 · Phase 3
59.1% (n=480) vs 63.2% (n=190) placebo @ 36wk100 mg
NCT02889796 · Phase 3
63.1% (n=480) vs 63.8% (n=190) placebo @ 52wk100 mg
NCT02889796 · Phase 3
EULAR Good 21.8% (n=147) vs 8.8% (n=148) placebo @ 4wk200 mg
responder rate · % of participants
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 32 Participants as posted
show 6 more results
30% (n=210) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · monotherapy · converted to % from 63 Participants as posted
24.6% (n=475) vs 7.8% (n=475) placebo @ 4wk*200 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 117 Participants as posted
22.2% (n=153) vs 8.8% (n=148) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02873936 · Phase 3 · converted to % from 34 Participants as posted
17.9% (n=480) vs 7.8% (n=475) placebo @ 4wk*100 mg
Week 4 · Good Response
NCT02889796 · Phase 3 · converted to % from 86 Participants as posted
28.8% (n=416) vs 10.8% (n=416) MTX @ 4wk*200 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 120 Participants as posted
21.7% (n=207) vs 10.8% (n=416) MTX @ 4wk*100 mg
Week 4 · Good Response
NCT02886728 · Phase 3 · combination · converted to % from 45 Participants as posted

+ 256 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: baricitinib's landscape · filgotinib's landscape